MedTrace Logo

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

NCT03555292 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-06-13

No results posted yet for this study

Summary

To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).

Conditions

  • Parkinson Disease

Interventions

DRUG

11C-PiB

11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans

Sponsors & Collaborators

  • Oriental Neurosurgery Evidence-Based-Study Team

    lead OTHER

Principal Investigators

  • Shuo Gao, MD · Tianjin Medical University General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-12
Primary Completion
2021-05-12
Completion
2021-10-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03555292 on ClinicalTrials.gov